Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLB-3000
- Development stage
- Unknown
- Lead developer
- ClearB Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**CLB-3000** is an investigational bivalent protein-subunit therapeutic vaccine from ClearB Therapeutics for chronic hepatitis B infection. It contains two proprietary engineered hepatitis B surface antigen variants, CLB-405 and CLB-505, designed to over-represent viral clearance-associated epitopes identified in individuals with functional cure, and is adjuvanted with Alhydrogel. The vaccine is intended to redirect or strengthen HBV-specific immune responses to promote functional cure, including reduction or clearance of hepatitis B surface antigen. CLB-3000 is being evaluated in an open-label Phase 1b study in adults with chronic hepatitis B receiving stable nucleoside or nucleotide analogue therapy. ([clearbtherapeutics.com](https://clearbtherapeutics.com/1313-2/))
- Other names
- CLB-405 + CLB-505 with Alhydrogel
02
Targets
HBsAg-specific BCR (HBsAg-specific B-cell receptor)Hepatitis B surface antigen-specific T-cell receptor
Beyond the preview
Go deeper on CLB-3000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLB-3000.